For the computer expert/CEO of Anima, Yochi Slonim, it’s all the same – lots of instructions and lots of code. It could be code for AI, it could be codons for the translation of proteins. With the elucidation of unique codon pairings by mRNA Lightning, Slonim can turn expression on or off, or up or down, depending on the therapeutic need, like say, in CNS disorders. Eli Lilly has taken notice. So has Takeda. You might want to give a listen…

Your GI team can’t help you if they can’t see what’s wrong. An endoscope might encounter clotted blood in the esophagus from chronic bleeds, or remaining stool in the colon after an insufficient prep. Either way, it would be nice to have a device that clears the way for precise imaging. The Pure-Vu® System, by Motus GI, offers both, and at a savings of time, and money. In this podcast, Tim Moran, CEO of Motus, tells us all about it.

Three facts: 1) World Diabetes Day is November 14th, which marks the 100th anniversary of the discovery and isolation of insulin. 2) There are an estimated 463 million diabetes patients worldwide – and that number is rapidly rising. 3) Access to care remains a major hurdle for diabetes patients, but today GBS is developing an affordable, smartphone-compatible, needle-free glucose monitor. Endocrinologist/ Interim CEO, Dr. Steven Boyages is here to tell you all about it.

He’s got patents, patience, and a plan – and a five-year runway to execute. Listen in as Dr. Amit Kumar, CEO of Anixa Biosciences, tells a tale of novel vaccines for breast, and ovarian cancer, and a new kind of CAR-T therapy – also for ovarian cancer – called a CER-T: a Chimeric Endocrine Receptor T cell. Is it worth your investment? Cleveland Clinic, Moffit Cancer Center, and investigators at NIH seem to think so…

From a doctorate at the SALK Institute overlooking La Jolla Cove, to an MBA from INSEAD, the world-leading business school located near Paris, NOXXON CEO Aram Mangasarian knows his way around different environments. Now he’s focused on tackling the tumor micro-environment (TME) and targeting the chemokines that drive tumor immunosuppression. Lead asset, NOX-A12, has generated exciting early results in some of the most challenging tumor types: pancreatic cancer and glioblastoma.

After spending the first half of her career developing medical devices for others, Kathy Lee-Sepsick, founder, and CEO of Femasys sets out to address the often-overlooked needs of a woman’s reproductive health – and she can’t be more passionate about the mission. Not only is Lee-Sepsick the company’s founder and CEO, but she’s also the inventor of Femasys’ two key reproductive health technologies: FemBloc, a permanent form of birth control that is much less invasive, and less expensive than the current standard of care, and Femaseed, a technology targeted to help women with reproductive difficulties conceive.

From a famous pub in Oxford to a lab on California’s coast, Gritstone founder, and CEO Dr. Andrew Allen tells the story of how his dream, inspired by a legend in cancer immunotherapy, became the reality that is Gritstone bio, a company developing both off-the-shelf and personalized vaccines for cancer – and now COVID – with antigens discovered by their proprietary, machine learning platform, EDGE™.

Listen in while Vincerx CEO, Dr. Ahmed Hamdy shares his experience with life-changing events, a date with the cancer target CDK9, and the utterance of every investor’s favorite magic word: “Platform.”

Combining his medical expertise with his business acumen, Angion’s CEO, Dr. Jay Venkatesan, is focused on meaningfully improving both health outcomes for patients in need and economic outcomes for the healthcare system. After successes at McKinsey, Bain, Ayer Capital, and Alpine BioVentures, Dr. Venkatesan is now seizing on what he describes as a rare opportunity to lead Angion, whose products have the potential to transform care for millions of patients. He was originally attracted to Angion – a 20-year old biotech company – as an investor due to its HGF mimetic technology being developed to treat acute organ injuries, including acute kidney injury. Dr. Venkatesan then joined Angion as its CEO after realizing the true potential of Angion’s science and its rich research and clinical development pipeline. I spoke with Dr. Venkatesan recently, ahead of two key Q4 data readouts from Angion’s lead HGF mimetic program.

Dr. Marshall Fordyce, CEO of Vera Therapeutics still treats patients – it is a calling he will always hear. It took him to the bedside at HIV clinics in the East to leadership roles in developing life-saving drugs at Gilead in the West. Entrepreneurship flowed from experience, and Vera Therapeutics came to be. Focused on nephrotic autoimmune disease, hear how Fordyce brought his heart and mind to this urgent unmet need.